Key Drivers
- Net Cash
- Fragile Profitability
- Cash Burn
AIAI Summary
PTGX has evolved from a pure pipeline bet into a more investable, catalyst-driven story thanks to ICOTYDE approval, a strong ~$620M cash runway, and rusfertide's upcoming FDA decision, but with the stock already re-rated, the key question is now whether management can convert these near-term wins into durable cash flow without an execution or regulatory setback.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Net Cash
- •Fragile Profitability
- •Cash Burn
PTGX has an exceptionally strong net-cash balance sheet and improved latest-quarter results, but profitability remains fragile, cash flow volatile, and the stock looks expensive versus current fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Range-bound trade
- •Sticky resistance
- •Support holding
PTGX has been range-bound over the last month, holding support around $98-$100 but repeatedly stalling near $105.5-$106.0, so a breakout or breakdown is likely to define the next move.
Rebounded from $98.37 to $105.55, then slipped back to $102.18 after testing resistance
Sentiment & News
Key News Insights:
- •FDA approval
- •Rusfertide progress
- •Cash runway
Protagonist Therapeutics is advancing key immunology assets with FDA approvals, priority-review rusfertide progress, and a strong cash position that supports runway through 2028.
This news is broadly positive for Protagonist Therapeutics, as clinical and regulatory momentum plus milestone inflows strengthen near-term valuation support and execution visibility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings